Patients with chronic kidney disease (CKD) and anemia experience substantially increased burdens to morbidity and mortality. Erythropoiesis-stimulating agents (ESA) and iron supplementation are mainstays of therapy, yet ESA has been associated with increased cardiovascular adverse events. Increased understanding of hypoxia-inducible factors (HIFs) has led to the development of novel therapies, hypoxia-iducible factor prolyl hydroxylase inhibitors (HIF-PHIs) that work by simulating hypoxia in cells, thereby stimulating EPO synthesis and improving iron metabolism and mobilization through reduced hepcidin levels.
Three HIF-PHIs (i.e. roxadustat, vadadustat, and daprodustat) are currently undergoing late-stage development, with one agent already approved to treat anemia in patients with CKD in China. To be best prepared to incorporate these agents into clinical practice once FDA-approved, nephrologists must be educated on the pathophysiological mechanisms involved in CKD-related anemia and recent outcomes from clinical trials evaluating these agents in patients with CKD. This educational activity will address these knowledge gaps among nephrologists, and application of this knowledge will improve outcomes for patients with anemia and CKD.
Volker Haase, MD
Professor of Medicine
School of Medicine
This educational activity is intended for nephrology fellows, attendings, and trainees.
Upon completion of this educational activity, participants should be able to:
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Integrity Continuing Education, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to receive credit for this activity, the participant must view the webinar, participate in program polling questions, and complete the evaluation form at the end of the program. A statement of credit will be issued only upon submission of a completed activity evaluation form and will be sent to you within four weeks of receipt of the completed evaluation.
There is no fee for this educational activity.
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or email@example.com.
Integrity Continuing Education requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent COI they may have as related to the content of this activity. All identified COI are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Volker Haase, MD
Consulting Fees: AstraZeneca, Akebia, Incyte Corporation, Rockwell
Integrity Continuing Education planners and managers (along with their spouses/life partners) reported no financial relationships nor relationships to products or devices with commercial interests related to the content of this CME activity.
When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)
Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10
Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Flash Player 10
Use of Internet Explorer browser is not recommended.
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Provided by Integrity Continuing Education, Inc.
This activity is supported by an educational grant from AstraZeneca.